Metropolis Healthcare · NSE: METROPOLIS · BSE: 542650
Q2 FY23 results · Jul–Sep 2022
Metropolis Healthcare reported revenue from operations of ₹300.35 crore (down 0.8% from Q2 FY22) and net profit of ₹40.48 crore (down 30.7% from Q2 FY22) for Q2 FY23 (Jul–Sep 2022), on a consolidated basis.
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 300.35 | 302.62 | −0.8% | 279.86 | +7.3% |
| Other income | 4.34 | 5.57 | −22.2% | 3.04 | +42.7% |
| Total income | 304.68 | 308.19 | −1.1% | 282.90 | +7.7% |
| Profit before tax | 54.80 | 77.71 | −29.5% | 42.83 | +27.9% |
| Net profit for the period | 40.48 | 58.40 | −30.7% | 33.56 | +20.6% |
| Attributable to shareholders of the company | 40.33 | 58.27 | −30.8% | 33.40 | +20.8% |
| EPS, basic (₹) | 7.88 | 11.39 | −30.8% | 6.53 | +20.7% |
| Net margin (%) | 13.5 | 19.3 | 12.0 |
| Item | Q2 FY23 | Q2 FY22 | YoY | Q1 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 280.06 | 241.96 | +15.7% | 257.02 | +9.0% |
| Other income | 2.93 | 3.30 | −11.2% | 2.42 | +20.9% |
| Total income | 282.99 | 245.26 | +15.4% | 259.44 | +9.1% |
| Profit before tax | 50.67 | 59.46 | −14.8% | 35.58 | +42.4% |
| Net profit for the period | 37.82 | 44.47 | −15.0% | 28.38 | +33.3% |
| EPS, basic (₹) | 7.39 | 8.70 | −15.1% | 5.54 | +33.4% |
| Net margin (%) | 13.5 | 18.4 | 11.0 |
Consolidated
- Filed with BSE
- 09 Nov 2022, 17:43 IST
- Board meeting
- 08 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2022, 17:43 IST
- Board meeting
- 08 Nov 2022
- Period
- 01 Jul 2022 to 30 Sep 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE